No Data
No Data
Buy Rating Affirmed for GH Research Amid Promising Trials and Regulatory Milestones
GH Research Is Maintained at Buy by Canaccord Genuity
GH Research Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on GH Research, Raises Price Target to $31
Express News | GH Research PLC : Canaccord Genuity Raises Target Price to $31 From $30
Analysts Offer Insights on Healthcare Companies: Veru (VERU) and GH Research (GHRS)
Express News | GH Research PLC - Phase 2a Clinical Trial of GH001 in Postpartum Depression on Track for Expected Completion in Q3 2024